MedAI Verdict

AI Radiology · 58 tools

Editorial illustration: a chest radiograph alongside a magnifying glass highlighting flagged regions in blue.

Infervision

Infervision logo
57/ 100

Evidence & Documentation Score

This legacy score reflects documented evidence, integrations, transparency, and market signals. It does not measure overall product performance. A new product-focused rating system is in development. How it is computed

reviewed November 2, 2026

Vendor
Infervision
Pricing
No public price.
EHR
Not stated
Compliance
FDA 510(k)

Bottom line. Infervision sells InferRead for CT lung nodules and CT stroke triage, InferOperate Suite for 3D surgical planning and InferCare for RECIST follow-up. FDA's records list six clearances, from InferRead Lung CT.AI in July 2020 (K192880) to a second InferOperate Suite entry in July 2026 (K260973). The chest X-ray product, InferRead DR Chest, has no FDA record under Infervision's applicant names… Read the full bottom line

Performance profile

  • Regulatory and compliance18 / 28
  • Clinical integration0 / 6.6
  • Evidence strength12.7 / 26
  • Vendor and market14.4 / 18
  • Sentiment and transparency2.5 / 5

Performance profile

  • Regulatory and compliance18 / 28
  • Clinical integration0 / 6.6
  • Evidence strength12.7 / 26
  • Vendor and market14.4 / 18
  • Sentiment and transparency2.5 / 5
On this page

All 9 dimensions

Regulatory and compliance

  • FDA clearance18 / 18

    FDA cleared (6 510(k) clearances on record)

  • HIPAA / SOC2 / BAA0 / 10

    No public HIPAA/SOC2/BAA attestation

Clinical integration

  • EHR integrations (count)0 / 4.2

    No EHR integrations listed

  • Top-3 EHR coverage (Epic / Oracle / Athena)0 / 2.4

    None of the top-3 EHRs covered

Evidence strength

  • Peer-reviewed papers12.7 / 18.2

    2 peer-reviewed papers evaluating the product; 2 not counted (product only mentioned or used, or not yet classified)

  • RCT / meta-analysis / systematic review0 / 7.8

    No RCT, meta-analysis, or systematic review evaluating the product

Vendor and market

  • Funding & adoption signal8.4 / 12

    Mid-tier funding and adoption

  • Years in market6 / 6

    Founded 2016 (10 years)

Sentiment and transparency

  • Pricing transparency2.5 / 5

    Pricing on request, no public amounts

Computed November 6, 2026 by our public rubric. How it’s computed

What it costs

From
No public price.
Price points
1
Verified
November 2, 2026
Source
Vendor pricing page

All tiers are custom-quoted. The vendor does not publish per-provider list pricing.

TierMonthlyAnnualNotes
EnterpriseNot statedNot statedNo public price.

Source: vendor pricing page. Last checked November 2, 2026.

Compliance

Attested
FDA 510(k)
EHR integrations
Not stated
FDA
6 decisions on record

Carries FDA 510(k) per vendor documentation. Independent attestation review is the buyer's responsibility before clinical deployment.

Vendor stability

Company
Infervision
Headquarters
Not stated
Founded
2016

Infervision (Infervision) was founded in 2016, putting it 10 years into market.

Vendor siteglobal.infervision.com (opens in new tab)

Evidence record

RecordWhat we found
FDA decisions
Show 1 more
Peer-reviewed

4 studies on PubMed: 4 other, published 2022 to 2026. Read the literature summary

Verification
  • Score computed November 6, 2026, method 1.2.1
  • Review written November 2, 2026
Cite this record

MedAI Verdict, Infervision record, https://medaiverdict.com/tools/infervision, version November 2, 2026

Change historyView every change to this record

Peer-reviewed coverage

PubMed lists 4 papers that name Infervision, shown by relevance (title match, study design, recency, journal tier). 2 of them evaluate the product itself; the others only mention it, use it as a tool or do not identify it clearly, and do not count as evidence.

YearJournalTitleAuthors
2026J Thorac DisSpatial classification of clinical T1a-bN0 non-small cell lung cancer in superior segment based on three-dimensional reconstruction: optimizing surgical margin and operative strategy. (opens in new tab)In segmentectomies of the superior segment (S) for early-stage non-small cell lung cancer (NSCLC), inadequate surgical margins remain a critical challenge. This study aims to establish a three-dimensional (3D) spatial classification system for Stumors to analyze margin adequacy and optimize surgical planning. This retrospective cohort study included 699 patients with clinical T1a-bN0 SNSCLC who underwent thoracoscopic surgery between 2019 and 2023. Tumors were classified into three categories using the "InFerVision" software. S-I had a margin sphere located above the intersegmental plane. S-I…Yang Y, Ren Q, Wang Z, et al.
2026Front OncolAI-assisted clinico-quantitative imaging nomogram for preoperative malignancy risk in solid and part-solid pulmonary nodules ≤ 3 cm: development and internal validation. (opens in new tab)To develop and internally validate an artificial intelligence (AI)-assisted clinico-quantitative imaging prediction model that combines automatically extracted quantitative imaging features with clinical data to preoperatively assess individualized malignancy risk in solid and part-solid pulmonary nodules (PNs) measuring ≤ 3 cm. This retrospective study analyzed data from 951 consecutive patients who underwent surgical resection for PNs ≤ 3 cm (210 benign, 741 malignant). Quantitative CT features, including nodule size, minimum and maximum computed tomography attenuati…Ruan Y, Long C, Cao W, et al.
2022Diagn Interv ImagingImpact of dose reduction and iterative reconstruction algorithm on the detectability of pulmonary nodules by artificial intelligence. (opens in new tab)The purpose of this study was to assess whether the performances of an automated software for lung nodule detection with computed tomography (CT) are affected by radiation dose and the use of iterative reconstruction algorithm. A chest phantom (Multipurpose Chest Phantom N1; Kyoto Kagaku Co. Ltd, Kyoto, Japan) with 15 pulmonary nodules was scanned with a total of five CT protocol settings with up to 20-fold dose reduction. All CT examinations were reconstructed with iterative reconstruction algorithms ADMIRE 3 and ADMIRE 5 and were then analyzed for the presence of pulmonary nodules with a fu…Schwyzer M, Messerli M, Eberhard M, et al.
2023Quant Imaging Med SurgCoronary computed tomography angiography analysis using artificial intelligence for stenosis quantification and stent segmentation: a multicenter study. (opens in new tab)Accurate interpretation of coronary computed tomography angiography (CCTA) is a labor-intensive and expertise-driven endeavor, as inexperienced readers may inadvertently overestimate stenosis severity. Recent artificial intelligence (AI) advances in medical imaging present compelling prospects for auxiliary diagnostic tools in CCTA. This study aimed to externally validate an AI-assisted analysis system capable of rapidly evaluating stenosis severity, exploring its potential integration into routine clinical workflows. This multicenter study consisted of an internal and external cohort of pati…Meng Q, Yu P, Yin S, et al.

See all on PubMed (opens in new tab)

Bottom line

Infervision sells InferRead for CT lung nodules and CT stroke triage, InferOperate Suite for 3D surgical planning and InferCare for RECIST follow-up. FDA's records list six clearances, from InferRead Lung CT.AI in July 2020 (K192880) to a second InferOperate Suite entry in July 2026 (K260973). The chest X-ray product, InferRead DR Chest, has no FDA record under Infervision's applicant names. A hospital building a CT lung nodule workflow or a thoracic surgery planning service fits the cleared range. Chest X-ray AI under a US clearance is not part of what the record offers.

AI for CT lung nodules, CT stroke, surgical planning and RECIST follow-up, with FDA clearances for these CT products.

No public price.

What do the CT products do?

Infervision says InferRead CT Lung detects pulmonary nodules (pure ground glass, solid, mixed and suspected tumor), analyses lobe density and volume, registers follow-up scans with volume doubling time and produces a structured report in a browser viewer. Quantification of nodule growth, emphysema and coronary calcium is marked "For investigational use only" on the product page. The vendor claims 99% sensitivity with AI assisted reading, citing a linked publication, and a 33% cut in reading time from a talk by Wake Radiology.

Infervision says InferRead CT Stroke triages hemorrhage on head CT. FDA lists InferRead CT Stroke.AI (K211179, August 2021) as triage and notification. The Lung CT page shows FDA, NMPA and UKCA badges and no CE mark. The vendor calls the products "PACS and RIS friendly", on premise or in the cloud.

What is known about the chest X-ray product?

A 2025 PLOS Global Public Health study (PMID 40531944) by independent academic authors evaluated InferVision CAD, the InferRead DR Chest product, for tuberculosis screening in Lusaka, Zambia. At a cutoff of 0.12, sensitivity was 90.3% (86.3 to 93.5) and specificity 39.2% (36.8 to 41.7), with an AUC of 0.81. FDA has no entry for it under Infervision's applicant names.

Who is the company and what does it charge?

Infervision says it was founded in 2016, and its company page does not state a headquarters. The vendor claims deployments including Wake Radiology, Sanford Health research and TB screening in Kyrgyzstan and Zimbabwe. It publishes no price, and the site lists a contact address for enquiries.

The verdict

Thoracic surgery teams get planning software with two InferOperate Suite entries, and CT lung screening programs get nodule detection with clearances going back to July 2020. For chest X-ray AI the picture is the Zambia tuberculosis study (PMID 40531944) and no FDA record under Infervision's applicant names.

Editorial review last generated November 2, 2026. Synthesized from clinician sentiment, peer-reviewed coverage, and our editorial silo picks. Refined by hand where vendor facts change.

Link to this review

Infervision, reviewed on MedAI Verdict

Vendors may place this badge on their own site. It links to this review with a tracking parameter and has no effect on the score.

<a href="https://medaiverdict.com/tools/infervision?utm_source=vendor_badge&utm_medium=badge&utm_campaign=infervision"><img src="https://medaiverdict.com/badges/reviewed-on-medaiverdict.png" srcset="https://medaiverdict.com/badges/reviewed-on-medaiverdict@2x.png 2x" alt="Infervision, reviewed on MedAI Verdict" width="200" height="56"></a>

What we have not verified

  1. We have not run Infervision in our own clinical practice. Pricing, certifications, and EHR-integration claims come from vendor documentation and have not been independently audited.
  2. Enterprise pricing tiers and SLA terms are typically under NDA and not publicly verifiable. Numbers shown reflect publicly disclosed self-service or list pricing only.
  3. Real-world latency, note quality, and accuracy in your specific specialty and patient population can vary materially from vendor demonstrations. We recommend a 30-day trial with two providers before commitment.

Last verified . Read our methodology · Radiology